Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
| dc.contributor.author | Taweesuk A. | |
| dc.contributor.author | Rattanaumpawan P. | |
| dc.contributor.author | Rachakhom S. | |
| dc.contributor.author | Wangchinda W. | |
| dc.contributor.author | Assanasen S. | |
| dc.contributor.author | Thamlikitkul V. | |
| dc.contributor.correspondence | Taweesuk A. | |
| dc.contributor.other | Mahidol University | |
| dc.date.accessioned | 2026-05-11T18:15:00Z | |
| dc.date.available | 2026-05-11T18:15:00Z | |
| dc.date.issued | 2026-04-15 | |
| dc.description.abstract | Background: Carbapenem-resistant Enterobacterales (CRE) colonization is a major risk factor for infection. Most infection prevention and control (IPC) strategies rely on private-room isolation, but evidence of their effectiveness in resource-limited settings is scarce. Methods: From February to October 2021, we conducted a cluster-randomized controlled trial in 6 general medical wards at Siriraj Hospital, enrolling adults with ≥1 CRE risk factor. Wards were randomized to standard infection control care (sIC) or an enhanced CRE prevention program (eIC) comprising sIC plus monthly staff education, real-time notifications of CRE acquisition, and contact-precaution reminders. Active stool/rectal CRE surveillance was performed at enrollment and weekly. Primary outcomes were the CRE acquisition incidence and CRE acquisition–free time. Results: A total of 363 patients were included: 174 in the intervention group (1684 patient-days) and 189 in the control group (1517 patient-days). The cumulative incidence of CRE acquisition was slightly lower in the intervention group (36.8% vs 46.6%; P = .06), with a significantly lower incidence rate per patient-day (0.038 vs 0.058; P = .007). In a post hoc analysis excluding acquisitions within 24 hours, the cumulative incidence was similar between groups (25.7% vs 33.6%; P = .16). The probability of remaining CRE-free showed an unadjusted hazard ratio (HR) of 0.72 [95% CI, 0.52–1.00; P = .05]. After adjusting for prior antibiotic use, the adjusted HR was 0.75 [95% CI, 0.54–1.05; P = .09]. There were no differences in all-cause mortality or length of hospital stay. Conclusions: Carbapenem-resistant Enterobacterales acquisition incidence was high in this setting. The enhanced CRE prevention program tended to reduce CRE acquisition and prolong CRE-free survival. Larger studies are needed to explore benefits on morbidity and mortality. | |
| dc.identifier.citation | Clinical Infectious Diseases Vol.82 No.4 (2026) , e757-e764 | |
| dc.identifier.doi | 10.1093/cid/ciaf523 | |
| dc.identifier.eissn | 15376591 | |
| dc.identifier.issn | 10584838 | |
| dc.identifier.pmid | 40982552 | |
| dc.identifier.scopus | 2-s2.0-105037802878 | |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/123456789/116665 | |
| dc.rights.holder | SCOPUS | |
| dc.subject | Medicine | |
| dc.title | Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital | |
| dc.type | Article | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105037802878&origin=inward | |
| oaire.citation.endPage | e764 | |
| oaire.citation.issue | 4 | |
| oaire.citation.startPage | e757 | |
| oaire.citation.title | Clinical Infectious Diseases | |
| oaire.citation.volume | 82 | |
| oairecerif.author.affiliation | Siriraj Hospital |
